

Exercise Induced Bronchoconstriction: A clinical approach

**Andriana I. Papaioannou,
Konstantinos Bartziokas,
Stelios Loukides,
Spyridon Papiris,
Konstantinos Kostikas**

2nd Respiratory Medicine Department,
University of Athens, Medical School, "Attikon"
Hospital

Key words:

- Exercise induced bronchoconstriction
- Asthma
- Bronchodilators
- Indirect challenge tests

SUMMARY. Exercise-induced bronchoconstriction (EIB) describes the acute airway narrowing which occurs as a result of exercise. EIB commonly affects individuals with and without clinically recognized asthma, especially those who participate in competitive athletics. EIB is believed to be caused by the loss of water from the lower airways which is the result of heating and humidifying large volumes of air in a short period. The aforementioned procedure results in a hyperosmolar environment which activates various cellular mechanisms to release inflammatory mediators which in turn lead to airway smooth muscle contraction and bronchoconstriction. In elite athletes EIB may also develop from a process of airway injury and changes in the contractile properties of airway smooth muscle. Short acting β_2 -agonists are recommended first-line agents for pharmacologic treatment, although leukotriene receptor antagonists or inhaled corticosteroids with or without long-acting β_2 -agonists may be needed in refractory cases. If symptoms persist despite treatment, alternative diagnoses should be considered. In this review we summarize the pathophysiology, the clinical manifestations, the diagnostic approach and the treatment strategies of EIB. *Pneumon* 2014, 27(2):139-146.

INTRODUCTION

The term exercise-induced bronchoconstriction (EIB) is used to describe the transient and reversible narrowing of the lower airways that follows vigorous exercise, regardless of the presence or absence of clinically recognized asthma¹. The term "exercise induced asthma" used in the previous years has now been replaced by the term "exercise induced bronchoconstriction". This change in the nomenclature of this condition seems to be accurate since exercise induced asthma refers to bronchospasm that occurs in patients with asthma when they exercise²; however, exercise induced bronchoconstriction can also occur in patients without underlying chronic asthma³. Thus, patients with exercise induced bronchoconstriction are patients who might not have evidence of asthma according to the current asthma guidelines,

Correspondence

Konstantinos Kostikas
3 Stamouli Street, Karditsa 43100, Greece
Tel: +30-6944780616; Fax: +30-2441022370
e-mail: ktk@otenet.gr

have normal pulmonary function tests at rest, do not have any symptoms during their everyday physical activity, do not need to use β_2 -agonists other than with exercise and have a normal asthma control test (or other questionnaire used for the assessment of asthmatic symptoms)².

EIB occurs in approximately 90% of asthmatic subjects and in 40% of patients with allergic rhinitis⁴. Asthmatic patients with more severe or poorly controlled asthma are more likely to exhibit EIB than those with less severe or well-controlled disease⁵. In the general population the prevalence of EIB ranges from 7% to 20%⁴. Studies have shown that in elite-level athletes the prevalence of EIB varies between 30 and 70%, depending on the population studied, the type of sport, the environmental conditions and the methods implemented^{4,6}.

PATHOPHYSIOLOGY

Two main theories have been used to explain the mechanism of EIB: the thermal theory and the osmotic theory. The thermal theory, proposes that the cooling of the airway, which occurs as a result of water loss, causes vasoconstriction in bronchial vasculature. On rewarming, airway narrowing will occur due to the mechanical effects of vascular engorgement, vascular leakage, and edema of

the airway wall.¹ Thus, in this scenario, airway narrowing would occur as a direct consequence of vascular events and would be unrelated to mediator release or airway smooth muscle contraction. On the other hand, the osmotic theory proposes that airway water loss results in increased osmolarity of the airway surface liquid, which extends to include the airway epithelial cells and submucosa. This hyperosmolar environment activates cellular mechanisms to release various mediators. These mediators, in turn, cause airway smooth muscle contraction and subsequent airway narrowing¹. The aforementioned theories are summarized in Figure 1.

In elite athletes, the development of EIB seems to be caused by another mechanism, which includes airway injury and airway hyperresponsiveness. During intense physical activity conducted over prolonged amounts of time, the smaller airways are increasingly recruited in the humidification process. This process is repetitive during training and results in dehydration injury to the airway epithelium¹. Epithelial repair of this airway injury involves microvascular leak and plasma exudation. Epithelial injury results in a reduced capacity to move water to the airway to respond to a hyperosmolar stimulus. With repeated injury, a larger airway surface area will need to be recruited in the conditioning process, thereby causing continued




FIGURE 1. Pathophysiology of exercise induced bronchoconstriction.

progression of the airway injury¹. This repeated exposure of airway smooth muscle cells to injury results in airway hyperresponsiveness in elite athletes. This airway hyperresponsiveness is reversible and does not occur any more when the athlete is out of season or after retirement.

DIAGNOSIS

Symptoms of EIB do not differ from those of usual asthma and include shortness of breath, cough, wheeze, and mucus production³. Atypical symptoms such as poor performance or feeling 'out of shape', abdominal pain, headache, muscle cramps, fatigue and dizziness may also occur². Symptoms of EIB begin usually 6-8 min after strenuous exercise⁷. In some cases, patients recognize asthma symptoms during exercise and those symptoms continue to increase even after the intensity of exercise is reduced.

However, symptoms are neither sensitive nor specific and often are caused from vigorous exercise rather than EIB⁹. This is the reason why the diagnosis of EIB requires documentation of changes in lung function after exercise. It is important to point out that in a recent study only 35% of athletes reporting symptoms suggestive of EIB had objectively documented EIB after pulmonary function testing⁸.

The diagnosis of EIB typically requires a decrease in forced expiratory volume in 1 second (FEV₁) at any 2

consecutive time points within 30 minutes after exercise of 10% to 15% of the pre-exercise FEV₁ value⁶. According to the ATS/ERS guidelines, FEV₁ is usually measured at 5, 10, 15, and 30 minutes after exercise, but may be more frequent if a severe response is expected³. However, there is no gold standard diagnostic procedure for the diagnosis of EIB and several tests can be used⁹. Diagnostic tests used for the diagnosis of EIB are summarized in Table 1.

Direct pharmacological challenge tests rely on the administration of agents (such as histamine and methacholine) which induce bronchoconstriction by acting directly on airway smooth muscle cells. Despite the fact that methacholine challenge testing is traditionally a very reliable test for the diagnosis of asthma, its role in the diagnosis of EIB is limited. Hence, a positive test does not specifically confirm EIB, whereas a negative test does not specifically exclude EIB⁹. Unlike direct challenge tests, indirect tests can accurately diagnose EIB¹⁰. Indirect challenge tests include exercise challenge tests, eucapnic voluntary hyperpnea and inhalation of hyper osmolar aerosols (4.5% saline or dry powder mannitol)^{3,10}. Although none of these tests are completely sensitive or specific for EIB, they are very useful for the identification of airway hyperresponsiveness consistent with a diagnosis of EIB³.

Exercise testing (either laboratory based i.e. treadmill cycle or ergometer) and field based testing (i.e. performing the sport activity) are very commonly used methods for the diagnosis of EIB⁹. During the exercise challenge test,

TABLE 1. Tests for the Diagnosis of Exercise-Induced Bronchoconstriction.

Indirect Tests	Advantages	Disadvantages
Eucapnic voluntary hyperpnea test	Sensitive and specific Less equipment needed	Need to monitor minute ventilation Relatively expensive
Field-based exercise challenge	Sensitive and specific for cold-weather athletes Minimal equipment Inexpensive	Not standardized Unable to control environment
Hypertonic saline test	Sensitive and specific Less equipment needed	Not as reliable if patient is treated with ICS
Laboratory-based exercise challenge	Sensitive and specific Standardized	Monitor heart rate and minute ventilation Relatively expensive
Direct Tests		
Methacholine challenge	Less equipment needed Standardized	Low Specificity
Histamine challenge	Less equipment needed Standardized	Low Specificity

ICS: Inhaled Corticosteroids

the patient undergoes a rapid increase in exercise intensity over approximately 2–4 minutes in order to achieve a high level of ventilation. Most protocols recommend breathing dry air (10 mg H₂O/L) with a nose clip in place while running or cycling at a load sufficient to raise the heart rate to 80–90% of predicted maximum or ventilation to reach 17.5–21 times FEV₁. Once this level of exercise is achieved, the subject should continue exercise at that high level for an additional 4–6 minutes. These targets are more rapidly achieved with running exercise compared with cycling³. FEV₁ is measured at baseline and at several time points after the exercise stimulus. One of the main limitations of this method is the failure to increase the exercise load to the needed level that will trigger the development of EIB⁹. Furthermore, during the field based tests, the workload and environmental conditions are difficult to control and measure and this might lead in false negative results⁹.

Eucapnic voluntary hyperventilation testing involves hyperventilation of a gas mixture of 5% carbon dioxide and 21% oxygen at a target of ventilation of 85% of the patient's MVV¹¹. This hyperventilation procedure continues for 6 min and FEV₁ measurements are performed in specific intervals up to 20 min after the test and are compared to baseline¹¹. Eucapnic voluntary hyperventilation testing has a high sensitivity to identify EIB and a high negative predictive value⁹. The major limitation of this method is that it required special equipment which is not widely available and might be expensive.

Mannitol and hypertonic saline (4.5% NaCl) inhalation are examples of osmotic challenge tests for the documentation of EIB. As a diagnostic tool, mannitol inhalation compares well with EVH and exercise testing¹²⁻¹⁴. Mannitol, is commercially available as a convenient and standardized test kit with prefilled dry powder capsules and single-use dry powder inhaler devices, which are portable¹⁵. This is a significant advantage over other bronchoprovocation techniques that require expensive equipment that is not portable.

Regarding the results in the indirect challenge testing, the severity of EIB can be graded as mild, moderate, or severe if the percent fall in FEV₁ from pre-exercise level is >10% but ≤25%, >25% but ≤50%, or >50%, respectively³. In case the patient receives medications for the treatment of asthma or rhinitis, the drugs should be withheld. The recommended times of drug withholding are presented in Table 2¹⁶.

Differential diagnosis of EIB includes several diseases such as anxiety disorders, cardiac diseases (e.g. conges-

TABLE 2. Minimum time intervals from last dose to the test performance

Medication	Time to withhold
Inhaled non-steroidal anti-inflammatory agents (e.g. sodium cromoglycate, nedocromil sodium)	8 hours
Short acting β ₂ -agonists (e.g salbutamol, terbutaline)	8 hours
Inhaled corticosteroids	12 hours
Ipratropium bromide	12-24 hours
Long acting β ₂ -agonists	24 hours
Theophylline	24 hours
Tiotropium bromide	7 days
Antihistamines (e.g. cetirizine, fexofenadine, loratadine)	72 hours
Leukotriene- receptor antagonists (e.g. montelukast sodium)	4 days

Coffee, tea, cola drinks, chocolate or other food containing caffeine should be withheld on the day of the test.

Vigorous exercise should not be performed prior to testing on the day of the test

Patients should refrain from smoking for at least 6 hours prior to testing.

*Modified from*¹⁶

tive heart failure, coronary artery disease, dysrhythmias, hypertrophic cardiomyopathy, valvular abnormalities etc.), deconditioning, obesity, hyperventilation syndrome, myopathies, pulmonary arteriovenous malformations, pulmonary disease (e.g. chronic asthma, chronic obstructive pulmonary disease, cystic fibrosis, interstitial lung disease, pectusexcavatum, scoliosis, tracheobronchiolar malacia, and vocal cord dysfunction^{10,17}. The differential diagnosis has to be always examined especially when bronchial provocation testing results are normal¹⁰.

A diagnostic algorithm for the evaluation of patients with suspected EIB is shown in Figure 2.

TREATMENT

EIB affects many aspects of a patient's life, and is a very important problem in athletes regardless of the severity of symptoms. Although EIB is usually mild or moderate, deaths have been also reported. The main goal of treatment is not only to ensure that the patient will exercise safely but also to help athletes of all levels to maximize their performance during athletic competitions¹⁰.




FIGURE 2. Diagnostic and therapeutic algorithm for exercise induced bronchoconstriction.

The treatment of EIB can be divided in two major categories the non-pharmacologic treatment and the pharmacologic treatment. Non pharmacologic options for the management of EIB include pre-exercise warm up, the use of heat exchange masks and nutritional methods. Typically, the pre-exercise warm-up consists of 10–15 minutes of moderately vigorous exercise, and subsequent EIB is reduced for the next 2 hours, resulting in a so-called “refractory period”³. Although various approaches of pre exercise warm up have been tried, including low-intensity, high-intensity, interval, or continuous exercise, and combinations of these, this intervention has not been proven to be effective in elite athletes, especially those exercising in cold water¹⁰.

Heat exchange masks are used to limit cold air exposure during exercise in athletes with EIB. These masks are commercially available, however, their use does not seem to be as effective as pre-treatment with salbutamol in the prevention of bronchoconstriction and sometimes are not practical to be used during competition^{10,18}.

Nutritional changes seem to reduce EIB. However, long term studies are lacking. The most important dietary intervention seems to be the intake of high dose of omega 3 fish oil supplementation. A recent study has shown that

high dose omega 3 fish oil supplementation for three weeks not only reduced the use of bronchodilators in the treatment group, but also resulted in a reduction of specific inflammatory biomarkers, including plasma LTB₄, TNF- α and IL1 β levels¹⁹. A second study has compared the effectiveness of fish oil to montelukast and has shown that both interventions had similar effects in the prevention of EIB and the combination of fish oil with montelukast did not confer a greater protective effect than either intervention alone²⁰. The potential antiinflammatory effect of omega 3 fish oil supplementation stems from its active ingredient, eicosapentaenoic acid, which is a competitive substrate with arachidonic acid for the generation of inflammatory mediators. The derivatives of arachidonic acid are LTB₄, a potent neutrophil chemoattractant, and proinflammatory mediator, and the cysteinyl series of Leucotriens (LTC₄, LTD₄, and LTE₄), which produce potent smooth muscle contraction and bronchoconstriction²¹. Arachidonic acid is the progenitor of LTB₄ via the 5-lipoxygenase enzymatic pathway. Eicosapentaenoic acid, can inhibit Arachidonic acid metabolism competitively via these enzymatic pathways and, thus, can suppress production of the n-6 eicosanoid mediators. Thus, increasing dietary ω -3 fats can shift the balance of the eicosanoids

produced to a less inflammatory mixture by reducing the production of proinflammatory Leucotriens¹⁹

Pharmacologic therapy is the most effective treatment for EIB and includes short-acting β 2-agonists (SABAs), long-acting β 2-agonists (LABAs), leukotriene receptor antagonists (LTRAs), and inhaled corticosteroids (ICSs). In the past mast cell stabilizing agents have been also used although today these agents are not preferred. Inhaled anticholinergic agents (such as ipratropium) and antihistamines, might play a minor role in treating some patients with EIB.

Short acting β 2-agonists (such as salbutamol) are recommended as first line treatment both as prevention and for the relief of acute symptoms. They should be administered shortly before exercise (approximately 15 min) since they have a peak action in 15-60 min which lasts approximately 4 hours¹⁰. These agents work by stimulating β 2-receptors on airway smooth muscle, causing muscle relaxation and bronchodilation as well as possibly preventing mast cell degranulation. However, short acting β 2-agonists may fail to prevent bronchoconstriction in 15–20% of patients with asthma. Furthermore, daily use of short acting β 2-agonists leads to tolerance, due to desensitization of the β 2-receptors on mast cells and airway smooth muscle, and this tolerance is manifested as a reduction in duration of protection against EIB, and a prolongation of recovery in response to SABA after exercise³. This is the reason why it is recommended that short acting β 2-agonists should be used in less than daily on average for the prevention of EIB. Patients who use SABAs on a more regular basis (e.g., daily) should be preferably treated with a controller agent, such as ICS or LTRAs³.

Long acting β 2-agonists have also been shown to be effective for the prevention of EIB; however, according to the asthma management guidelines, it is recommended that they should not be used unless there is a concomitant use of a controller medication, such as inhaled corticosteroids (ICS). Concurrent use of ICS plus long acting β 2-agonists has also been shown to be effective and superior to use of ICS alone in managing EIB¹⁰.

Mast cell stabilizers such as cromolyn sodium and nedocromil sodium when inhaled shortly before exercise attenuate EIB but their duration of action is short (1-2 hours). They do not have a bronchodilator activity. They may be effective alone or as added therapy with other drugs for EIB⁵. Long-term use of either drug is not accompanied by tolerance. Furthermore, these drugs have excellent safety profiles which in combination with their rapidity of action, results to their validity to attenuate

EIB in responsive individuals⁵. However, these drugs are not considered first-line options for the management of EIB today.

EIB which occurs in asthmatic patients is controlled by maintenance anti-inflammatory treatment either alone or in combination with other short-term preventive treatment. ICS use in asthma has been also associated with attenuation of hyper responsiveness to direct and indirect stimuli, including exercise. The effect of ICS on EIB seems to be dose and time dependent and may be associated with decreases in inflammatory mediators⁵. This bronchoprotective effect of ICS begins approximately 4 hours after the first dose and reaches a plateau after 1 week of long-term therapy. ICS can be also used in combination with adrenergic agonists or leukotriene receptor antagonists. However, it is important to state that inhaled corticosteroid therapy does not prevent the occurrence of tolerance from daily use of β 2-agonists.

A recent study has shown that in asthmatic patients with mild asthma who experienced EIB, the use of the fixed combination of formoterol and budesonide (6/200 μ g) given as needed was superior from the as needed use of terbutaline (a short acting β -agonist) alone and was equally effective with the everyday use of budesonide alone. The authors also conclude that except of this non inferiority in the use of as needed combination compared to the ICS alone, patients were also receiving lower doses of ICS which might be related to fewer adverse events caused by the ICS²².

Leukotriene receptor antagonists have been shown to have a persistent benefit against EIB. Montelukast has an onset of action within 2 hours and continues to have a preventive benefit for up to 24 hours after a single oral dose¹⁰. When used daily does not result to tolerance and can be used for intermittent or maintenance prophylaxis. However, it provides protection that may not be complete and although it has been shown to accelerate the time to recovery from EIB when it occurs, it has no use to reverse airway obstruction⁵. Finally short acting β 2-agonists have been shown to be more effective than montelukast in the prevention of EIB¹⁰.

Anticholinergics provide some protection against EIB but are not as effective as short acting β 2-agonists or leukotriene receptor antagonists¹⁰. Furthermore, not all patients appear to respond to anticholinergic agents, and responsiveness may be variable in the same patient⁵. Finally, antihistamines can be used as additional therapy in patients with EIB who have allergies and continue to have symptoms despite using an inhaled short acting

TABLE 3. Treatment of Exercise-Induced Bronchoconstriction.**Pharmacologic Therapy**

- Administration of an inhaled short-acting β 2-agonist (SABA) 15 minutes before exercise.
- Addition of a controller agent whenever SABA therapy is used daily or more frequently.
- For patients with EIB who continue to have symptoms despite using an inhaled SABA, or who require an inhaled SABA daily or more frequently:
 - The guidelines **recommend against** daily use of an inhaled long acting β 2-agonist as single therapy
 - It is recommend daily administration of an inhaled corticosteroid (**but** notonly before exercise)
 - Administration of a leukotriene receptor antagonist
 - Administration of a mast cell stabilizing agent before exercise
 - Administration of an inhaled anticholinergic agent before exercise
- For patients with EIB and allergies who continue to have symptoms despite using an inhaled SABA before exercise, administration of an antihistamine is suggested

Non Pharmacologic Therapy

- Warm-up exercise before planned exercise
- When exercising in cold weather, it is recommended routine use of a device (i.e., mask) that warms and humidifies the air during exercise
- For patients with EIB who have an interest in dietary modification to control their symptoms it is recommended
 - implementation of a low-salt diet
 - dietary supplementation with fish oils
 - dietary supplementation with ascorbic acid
 - **but against** dietary supplementation with lycopene

β 2-agonist before exercise³. Therapeutic interventions for the prevention of EIB are shown in Table 3.

CONCLUSION

EIB commonly affects individuals with and without asthma, and is very often in elite athletes. The initial stimulus for EIB stems from airway water loss that occurs when the lower airways must condition large volume of air in a short period. The resulting hyperosmolar environment activates various cellular mechanisms to release numerous mediators, which, in turn, lead to airway smooth muscle contraction and bronchoconstriction. Symptoms are not specific and diagnostic confirmation is necessary preferably using indirect challenge tests. Short acting β 2-agonists are recommended first-line agents for pharmacologic treatment, although leukotriene receptor antagonists or inhaled corticosteroids with or without long-acting β 2-agonists may be needed in refractory cases. Better understanding of the mechanisms of EIB would help in its more efficient treatment.

REFERENCES

1. Pongdee T, Li JT. Exercise-induced bronchoconstriction. *Ann Allergy Asthma Immunol* 2013; 110:311-315.
2. Storms W. Challenges in the management of exercise-induced asthma. *Expert Rev Clin Immunol* 2009; 5:261-269.
3. Parsons JP, Hallstrand TS, Mastrorarde JG, et al. An official American Thoracic Society clinical practice guideline: exercise-induced bronchoconstriction. *Am J Respir Crit Care Med* 2013; 187:1016-1027.
4. Randolph C. An update on exercise-induced bronchoconstriction with and without asthma. *Curr Allergy Asthma Rep* 2009; 9:433-438.
5. Weiler JM, Anderson SD, Randolph C, et al. Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter. *Ann Allergy Asthma Immunol* 2010; 105:S1-47.
6. Weiler JM, Bonini S, Coifman R, et al. American Academy of Allergy, Asthma & Immunology Work Group report: exercise-induced asthma. *J Allergy Clin Immunol* 2007; 119:1349-1358.
7. Lee SY, Kim HB, Yu J, et al. Exercise-induced asthma in children. *Expert Rev Clin Immunol* 2009; 5:193-207
8. Parsons JP, Kaeding C, Phillips G, et al. Prevalence of exercise-induced bronchospasm in a cohort of varsity college athletes. *Med Sci Sports Exerc* 2007; 39:1487-1492.
9. Parsons JP. Exercise-induced bronchospasm: symptoms are not enough. *Expert Rev Clin Immunol* 2009; 5:357-359.
10. Krafczyk MA, Asplund CA. Exercise-induced bronchoconstriction: diagnosis and management. *Am Fam Physician* 2011; 84:427-434.
11. Anderson SD, Argyros GJ, Magnussen H, et al. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. *Br J Sports Med* 2001; 35:344-347.

12. Holzer K, Anderson SD, Chan HK, et al. Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. *Am J Respir Crit Care Med* 2003; 167:534-537.
13. Holzer K, Douglass JA. Exercise induced bronchoconstriction in elite athletes: measuring the fall. *Thorax* 2006; 61:94-96.
14. Brannan JD, Koskela H, Anderson SD, et al. Responsiveness to mannitol in asthmatic subjects with exercise- and hyper-ventilation-induced asthma. *Am J Respir Crit Care Med* 1998; 158:1120-1126.
15. Anderson SD, Charlton B, Weiler JM, et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. *Respir Res* 2009; 10:4.
16. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. *Am J Respir Crit Care Med* 2000; 161:309-329.
17. Weiss P, Rundell KW. Imitators of exercise-induced bronchoconstriction. *Allergy Asthma Clin Immunol* 2009; 5:7.
18. Beuther DA, Martin RJ. Efficacy of a heat exchanger mask in cold exercise-induced asthma. *Chest* 2006; 129:1188-1193.
19. Mickleborough TD, Lindley MR, Montgomery GS. Effect of fish oil-derived omega-3 polyunsaturated Fatty Acid supplementation on exercise-induced bronchoconstriction and immune function in athletes. *Phys Sportsmed* 2008; 36:11-17.
20. Tecklenburg-Lund S, Mickleborough TD, Turner LA, et al. Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction. *PLoS One* 2010; 5:e13487.
21. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. *N Engl J Med* 1990; 323:1736-1739.
22. Lazarinis N, Jorgensen L, Ekstrom T, et al. Combination of budesonide/formoterol on demand improves asthma control by reducing exercise-induced bronchoconstriction. *Thorax* 2014; 69:130-136.